Maravai LifeSciences Reports Third Quarter 2026 Financial Results
Maravai LifeSciences reported Q3 2026 revenue of $45.9 million, up 10.1% year-over-year, with mRNA product revenue up 28%. Adjusted EBITDA swung to $5.8 million from $(10.8) million a year ago, though the company posted a GAAP net loss of $(24.0) million, or $(0.09) per Class A share.
Key figures
- Revenue
- 45851000
- Guidance
- FY2026 revenue raised to $212.0M-$216.0M (from $205.0M-$215.0M); Adjusted EBITDA raised to $40.0M-$42.0M (from $33.0M-$35.0M)
- Revenue Yoy
- 10.1%
- Adjusted ebitda
- 5820000
- Gross profit q3
- 16192000
- Cygnus growth q3
- 7.5%
- Cygnus revenue q3
- 17501000
- Trilink growth q3
- 11.8%
- Nine month revenue
- 163130000
- Trilink revenue q3
- 28350000
- Nine month revenue yoy
- 20.1%
- Mrna revenue growth yoy
- 28%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.